Posted by Michael Wonder on 10 Jan 2025
Tebentafusp for the treatment of patients with advanced uveal melanoma
9 January 2025 - NICE has published final evidence-based recommendations on the use of tebentafusp (Kimmtrak) for the treatment of adults with uveal melanoma.
Tebentafusp is recommended for the treatment of adults with unresectable or metastatic HLA‑A*02:01 positive uveal melanoma only if Immunocore provides it according to the commercial arrangement.
